AstraZeneca’s Symbicort Inhalation Aerosol is going to be available for 6-12 years old children with asthma in the US, as the US Food and Drug Administration (FDA) on Wednesday granted six months of paediatric exclusivity for it.
The FDA’s approval came after testing the Inhalation Aerosol in targeted group of children with asthma. Symbicort is currently approved in the US to treat asthma in patients 12 years and older and for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) in adults.
Symbicort was first approved by the FDA in the US in July 2006 for 12+ aged patients with asthma.